Empire Building: Jardiance To Take ‘Special Place’ In Heart Failure
Boehringer And Lilly 'Urgently' Submitting EMPEROR-Preserved Data
Executive Summary
Boehringer Ingelheim’s cardiometabolism head Mohamed Eid considers the impact of EMPEROR-Preserved study on the heart failure treatment landscape and looks ahead at potential new conquests in kidney disease for its SGLT2 inhibitor.
You may also be interested in...
Jardiance Gets Heart Failure Nod, But How Long Will Its Reign Last?
The SGLT2 inhibitor has better efficacy and clearer labeling than Novartis’s Entresto in heart failure with preserved ejection fraction, but AstraZeneca’s Farxiga is expected to produce Phase III data by June.
Cosentyx And Entresto Keep Powering Novartis As Firm Mulls Sandoz Sale
CEO Vas Narasimhan sees Novartis very much as an innovative company so the long-awaited strategic review of Sandoz suggests that the generics/biosimilars business could be spun off or sold fairly soon.
BI/Lilly's Jardiance Enters US Heart Failure Market Fray
Boehringer Ingelheim and Eli Lilly have gained a US approval for their SGLT2 inhibitor empagliflozin in heart failure with reduced ejection fraction, which could be extended further in coming months to other types of heart failure, adding to the products competing in this previously neglected therapeutic area.